

# Genetic Variation in Blood Pressure and Lifetime Risk of Peripheral Artery Disease: A Mendelian Randomization Study

Michael G. Levin, MD<sup>1,2,3</sup>; Derek Klarin, MD<sup>4,5</sup>; Venexia M. Walker, PhD<sup>6</sup>; Dipender Gill, BMBCh, PhD<sup>7,8,9,10,11</sup>; Julie Lynch, PhD<sup>12,13</sup>; Kyung M. Lee, PhD<sup>13,14,15</sup>; Themistocles L. Assimes, MD, PhD<sup>16,17,18</sup>; Pradeep Natarajan, MD<sup>19,20,21,22</sup>; Adriana M. Hung, MD<sup>23</sup>; Todd Edwards, PhD<sup>24</sup>; Daniel J. Rader, MD<sup>2,25,26</sup>; J. Michael Gaziano, MD, MPH<sup>22,27</sup>; Neil M. Davies, PhD<sup>6</sup>; Philip S. Tsao, PhD<sup>16,28</sup>; Kyong-Mi Chang, MD<sup>2,3</sup>; Benjamin F. Voight, PhD<sup>3,25,26,29</sup>; Scott M. Damrauer, MD<sup>3,30</sup>; on behalf of the VA Million Veteran Program

## Corresponding Author:

Scott M. Damrauer  
3900 Woodland Avenue  
Philadelphia PA 19104  
Phone: 215-823-5880  
[scott.damrauer@va.gov](mailto:scott.damrauer@va.gov)  
[damrauer@upenn.edu](mailto:damrauer@upenn.edu)

**Key Words:** Blood pressure; Genetics; Atherosclerosis; Peripheral Artery Disease

44 <sup>1</sup>Division of Cardiovascular Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA  
45 <sup>2</sup>Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA  
46 <sup>3</sup>Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA  
47 <sup>4</sup>Malcolm Randall VA Medical Center, Gainesville, FL  
48 <sup>5</sup>Department of Surgery, University of Florida, Gainesville, FL  
49 <sup>6</sup>Medical Research Council Integrative Epidemiology Unit, University of Bristol, Bristol, UK  
50 <sup>7</sup>Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, United  
51 Kingdom  
52 <sup>8</sup>Centre for Pharmacology & Therapeutics, Department of Medicine, Hammersmith Campus, Imperial College  
53 London, London, United Kingdom  
54 <sup>9</sup>Novo Nordisk Research Centre Oxford, Old Road Campus, Oxford, United Kingdom  
55 <sup>10</sup>Clinical Pharmacology and Therapeutics Section, Institute of Medical and Biomedical Education and Institute for  
56 Infection and Immunity, St George's, University of London, London, United Kingdom  
57 <sup>11</sup>Clinical Pharmacology Group, Pharmacy and Medicines Directorate, St George's University Hospitals NHS  
58 Foundation Trust, London, United Kingdom  
59 <sup>12</sup>Edith Nourse VA Medical Center, Bedford, MA  
60 <sup>13</sup>VA Informatics and Computing Infrastructure, Department of Veterans Affairs, Salt Lake City Health Care System,  
61 Salt Lake City, CT, USA  
62 <sup>14</sup>Center for Healthcare Organization and Implementation Research, Edith Nourse Rogers Memorial VA Hospital,  
63 Bedford, MA, USA  
64 <sup>15</sup>Department of Health Law, Policy & Management, Boston University School of Public Health, Boston, MA, USA  
65 <sup>16</sup>Palo Alto VA Healthcare System, Palo Alto, CA  
66 <sup>17</sup>Department of Medicine, Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford,  
67 CA  
68 <sup>18</sup>Stanford Cardiovascular Institute, Stanford University, Stanford, CA  
69 <sup>19</sup>Cardiovascular Research Center, Massachusetts General Hospital, Boston, MA  
70 <sup>20</sup>Broad Institute of Harvard and MIT, Cambridge, MA  
71 <sup>21</sup>Department of Medicine, Harvard Medical School, Boston, MA  
72 <sup>22</sup>VA Boston Healthcare System, Boston, MA  
73 <sup>23</sup>Division of Nephrology and Hypertension, Department of Medicine, Vanderbilt University Medical Center,  
74 Nashville, TN  
75 <sup>24</sup>Division of Epidemiology, Department of Medicine, Institute for Medicine and Public Health, Vanderbilt Genetics  
76 Institute, Vanderbilt University Medical Center, Vanderbilt University, Nashville, TN  
77 <sup>25</sup>Department of Genetics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA  
78 <sup>26</sup>Institute for Translational Medicine and Therapeutics, University of Pennsylvania Perelman School of Medicine,  
79 Philadelphia, PA  
80 <sup>27</sup>Division of Aging, Department of Preventive Medicine, Brigham and Women's Hospital, Harvard Medical School,  
81 Boston, MA  
82 <sup>28</sup>Department of Medicine, Division of Cardiovascular Medicine, and Stanford Cardiovascular Institute, Stanford  
83 University, Palo Alto, CA  
84 <sup>29</sup>Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania Perelman  
85 School of Medicine, Philadelphia, PA  
86 <sup>30</sup>Department of Surgery, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA  
87

88 **ABSTRACT:**

89 **Aims:** We aimed to estimate the effect of blood pressure and blood pressure lowering  
90 medications (via genetic proxies) on peripheral artery disease.

91

92 **Methods and Results:** GWAS summary statistics were obtained for BP (International  
93 Consortium for Blood Pressure + UK Biobank GWAS; N = up to 757,601 individuals), peripheral  
94 artery disease (PAD; VA Million Veteran Program; N = 24,009 cases, 150,983 controls), and  
95 coronary artery disease (CAD; CARDIoGRAMplusC4D 1000 Genomes; N = 60,801 cases, 123,504  
96 controls). Genetic correlations between systolic BP (SBP), diastolic BP (DBP), pulse pressure (PP)  
97 and CAD and PAD were estimated using LD score regression. The strongest correlation was  
98 between SBP and CAD ( $r_g = 0.36$ ;  $p = 3.9 \times 10^{-18}$ ). Causal effects were estimated by two-sample  
99 MR using a range of pleiotropy-robust methods. Increased SBP, DBP, and PP increased risk of  
100 both PAD (SBP OR 1.25 [1.19-1.31] per 10mmHg increase,  $p = 3 \times 10^{-18}$ ; DBP OR 1.27 [1.17-1.39],  
101  $p = 4 \times 10^{-8}$ ; PP OR 1.51 [1.38-1.64],  $p = 1 \times 10^{-20}$ ) and CAD (SBP OR 1.37 [1.29-1.45],  $p = 2 \times 10^{-24}$ ;  
102 DBP OR 1.6 [1.45-1.76],  $p = 7 \times 10^{-22}$ ; PP OR 1.56 [1.4-1.75],  $p = 1 \times 10^{-15}$ ). The effects of SBP and  
103 DBP were greater for CAD than PAD ( $p_{diff} = 0.024$  for SBP,  $p_{diff} = 4.9 \times 10^{-4}$  for DBP). Increased  
104 liability to PAD increased PP (beta = 1.04 [0.62-1.45] mmHg per 1 unit increase in log-odds in  
105 liability to PAD,  $p = 1 \times 10^{-6}$ ). MR was also used to estimate the effect of BP lowering through  
106 different classes of antihypertensive medications using genetic instruments containing BP-trait  
107 associated variants located within genes encoding protein targets of each medication. SBP  
108 lowering via calcium channel blocker-associated variants was protective of CAD (OR 0.38 per  
109 10mmHg decrease in SBP; 95% CI 0.19-0.77;  $p = 0.007$ ).

110 **Conclusions:** Higher BP is likely to cause both PAD and CAD but may have a larger effect on CAD  
111 risk. BP-lowering through calcium-channel blockers (as proxied by genetic variants) decreased  
112 risk of CAD.  
113

114 **INTRODUCTION:**

115           Peripheral artery disease (PAD) is a common manifestation of atherosclerotic  
116 cardiovascular disease (ASCVD), estimated to affect more than 12 million individuals in the  
117 United States, and more than 120 million individuals worldwide (1,2). PAD shares a number of  
118 risk factors with other forms ASCVD like coronary artery disease (CAD) and ischemic stroke (3).  
119 These risk factors include smoking, diabetes, hypertension, hyperlipidemia, and obesity (2–4).  
120 Observational studies have identified hypertension as one of the strongest risk factors for  
121 incident and prevalent PAD (5–11), although these studies may be limited by residual  
122 environmental confounding or reverse-causality. While randomized controlled trials of  
123 antihypertensive medications have demonstrated broad protection from coronary artery  
124 disease and death from cardiovascular causes, whether lower blood pressure reduces risk of  
125 PAD specifically has not been reliably established. Similarly, the relative effect of blood pressure  
126 on PAD and CAD has not been fully investigated.

127           Recent genome-wide association studies (GWAS) of PAD, CAD, and blood pressure  
128 including more than 700,000 individuals have identified hundreds of genetic variants associated  
129 with these traits (12,13). The Mendelian randomization (MR) framework (under certain  
130 assumptions) can leverage this genetic variation (which is randomly assorted during meiosis,  
131 mimicking a randomized trial), to provide unconfounded causal estimates of the relationship  
132 between traits (14). MR assumes that genetic variants are likely to be independent of many  
133 confounders of the exposure-outcome relationship. This assumption is plausible because  
134 genetic variants are randomly inherited by offspring from parents during meiosis and  
135 conception, analogous to treatment allocation in a randomized trial. Because large randomized

136 trials evaluating the relationship between treatment of hypertension and PAD outcomes may  
137 be unfeasible, other study designs are needed to fill this evidence gap. Here, we leverage  
138 population-scale genetic variation within the Mendelian randomization framework to 1)  
139 establish the relationship between blood pressure and risk of PAD, 2) quantify differences in  
140 the effect of blood pressure on CAD and PAD, and 3) estimate the effect of blood pressure  
141 lowering (using genetic proxies of antihypertensive medications) on PAD risk.

142

## 143 **METHODS:**

### 144 **Study Exposures**

145 The 2018 Evangelou et al. International Consortium for Blood Pressure + UK Biobank GWAS,  
146 which included measurements of systolic blood pressure, diastolic blood pressure, and pulse  
147 pressure in up to 757,601 individuals was used to identify genetic variants associated with the  
148 primary blood pressure phenotypes (15). This study included up to 299,024 European  
149 participants from 77 independent studies genotyped with various arrays and imputed to either  
150 the 1000 Genomes Reference Panel or the HRC panels, and 458,577 participants from the UK  
151 Biobank imputed to UK10K + 1000 Genomes reference panel. Measurement of blood pressure  
152 varied among cohorts, and study-specific details are presented in the supplemental material of  
153 Evangelou et al., 2018. Summary statistics for the blood pressure genome wide association  
154 study are publicly available, and may be downloaded from the NHLBI GRASP catalog  
155 (<https://grasp.nhlbi.nih.gov/FullResults.aspx>).

156

### 157 **Study Outcomes**

158 The 2019 Million Veteran Program genome wide association study of Peripheral Artery Disease  
159 by Klarin et al. identified 24,009 cases and 150,983 controls of European Ancestry (12). This  
160 study defined cases and controls based on electronic health record phenotyping within the  
161 Veterans Affairs (VA) Healthcare System and was validated against ankle brachial index  
162 measurement and manual chart review. The current analysis focused on participants of  
163 European ancestry. MVP PAD genome wide association study summary statistics are available  
164 on dbGAP (Accession phs001672.v2.p1).

165  
166 Genome-wide association study summary statistics for coronary artery disease were obtained  
167 from the Nikpay et al. 2016 CARDIoGRAMplusC4D 1000 Genomes-based GWAS. This study was  
168 a meta-analysis including 60,801 CAD cases and 123,504 controls, with genotypes imputed  
169 using the 1000 Genomes phase 1 version 3 reference. Summary statistics were downloaded  
170 from [www.cardiogramplusc4d.org/data-downloads/](http://www.cardiogramplusc4d.org/data-downloads/).

171

## 172 **Genetic Correlation**

173 LD-score regression was used to estimate the genetic correlation between blood pressure  
174 traits, and between blood pressure traits and ASCVD traits (<https://github.com/bulik/ldsc>)  
175 (16,17). GWAS summary statistics were obtained for systolic blood pressure, diastolic blood  
176 pressure, pulse pressure, peripheral artery disease, and coronary artery disease (12,13,15).  
177 Summary statistics were filtered to HapMap3 SNPs, and SNP heritability and genetic  
178 correlations were estimated using pre-computed 1000 Genomes European LD-scores.

179

## 180 Mendelian Randomization

181 Two-sample Mendelian randomization analyses were performed in R using the *TwoSampleMR*  
182 package (<https://github.com/MRCIEU/TwoSampleMR>) (18). Genetic instruments for SBP, DBP,  
183 and PP were constructed using linkage-disequilibrium independent ( $r^2 < 0.001$ , distance =  
184 10,000kb; 1000 Genomes European reference panel), genome-wide significant ( $p < 5 \times 10^{-8}$ )  
185 variants identified using GWAS summary statistics for each trait (**Supplemental Table 3**). For bi-  
186 directional MR analysis, additional instruments were constructed for CAD and PAD using the  
187 same procedure (**Supplemental Table 6**). For each variant included in the genetic instruments,  
188 proportion of variance explained was calculated using the formula  $R^2 =$   
189 
$$\frac{2\beta^2 MAF(1-MAF)}{2\beta^2 MAF(1-MAF) + 2NMAF(1-MAF)se^2}$$
 (where MAF represents the effect allele-frequency, beta  
190 represents the effect estimate of the genetic variant in the exposure GWAS, se represents the  
191 standard error of effect size for the genetic variant, and N represents the sample size)(19). F-  
192 statistics were calculated for each variant using the formula  $F = \frac{R^2 \times (N-2)}{1-R^2}$  (where  $R^2$  represents  
193 the variance in exposure explained by the genetic variant, and N represents the number of  
194 individuals in the exposure GWAS) to assess the strength of the selected instruments  
195 (**Supplemental Table 4**)(20). For the primary analysis, power calculation was performed to  
196 identify the minimum-detectable effect size maintaining 80% power with two-sided alpha of  
197 0.05. The primary MR analyses used inverse-variance weighting with random effects. The MR-  
198 Egger intercept test was used to evaluate for evidence of horizontal pleiotropy. Leave-one-out,  
199 single-SNP, and funnel-plot diagnostic MR analyses were performed. Sensitivity analyses were  
200 performed using MR methods that make different assumptions about the presence of  
201 pleiotropy (weighted median, penalized weighted median, and weighted mode) (21).

202 Multivariable MR (MVMR) was used in additional sensitivity analyses to jointly estimate the  
203 direct effects of multiple blood pressure traits, using genetic instruments including genomically  
204 independent ( $r^2 < 0.001$ , distance = 10,000kb) variants that were associated at genome-wide  
205 significance ( $p < 5 \times 10^{-8}$ ) with any exposure, weighted by the effect of each SNP on each  
206 exposure (**Supplemental Table 8**)(22). Effect estimates were scaled to correspond to a 10mmHg  
207 change in blood pressure.

208

### 209 **Antihypertensive Drug MR**

210 Two MR analyses were performed to estimate the effect of 10mmHg lower of blood pressure  
211 by antihypertensive drugs. In the first analysis, genetic instruments consisting of variants within  
212 genes encoding protein targets of ACE-inhibitors, beta-blockers, and calcium-channel blockers  
213 were obtained from Gill et. al., with each variant weighted by its effect on systolic blood  
214 pressure (**Supplemental Table 5**)(23). In a sensitivity analysis, genetic instruments were  
215 constructed that mimic the action of 12 antihypertensive medication classes. In contrast to the  
216 first method which selected genetic variants based on their proximity to genes encoding  
217 protein targets, this method prioritized variants representing expression quantitative trait loci  
218 (eQTL) for genes encoding protein targets of antihypertensive medications that were  
219 demonstrated to effect systolic blood pressure (24). For both methods, inverse-variance  
220 weighted and weighted-median MR was performed, with MR-Egger intercept test used to  
221 assess for horizontal pleiotropy. For instruments with only 1 variant, Wald-ratio MR was  
222 performed.

223

## 224 **Statistical Analysis**

225 All statistical analyses were performed using R version 3.6.2 (R Foundation for Statistical  
226 Computing).

227

## 228 **RESULTS:**

### 229 **Genetic Correlation**

230 Cross-trait LD-score regression was used to estimate the genetic correlation between  
231 blood pressure traits. All blood pressure traits (SBP, DBP, PP) were strongly, positively  
232 correlated (**Supplemental Figure 1; Supplemental Table 1**). The strongest correlation among  
233 blood pressure traits was between systolic blood pressure and pulse pressure ( $rg = 0.85$ ;  $p < 1.0$   
234  $\times 10^{-300}$ ).

235 Genetic correlation between blood pressure traits and ASCVD traits (CAD and PAD) was  
236 then assessed. All BP traits were strongly, positively correlated with ASCVD traits  
237 (**Supplemental Figure 2; Supplemental Table 2**). The strongest correlation among BP and  
238 ASCVD traits was between systolic blood pressure and CAD ( $rg = 0.36$ ;  $p = 3.9 \times 10^{-18}$ ).

239

### 240 **Effects of Blood Pressure on ASCVD: Mendelian Randomization**

241 To determine whether the genetic correlations between BP and ASCVD traits would be  
242 consistent with causal effects, we performed two-sample mendelian randomization using  
243 genome-wide association study summary statistics. Genetic instruments for blood pressure  
244 contained between 342 and 410 independent genetic variants, explaining between 3.5% and  
245 4.3% of the variability in blood pressure, with F-statistics ranging from 29.6 to 670.6 (consistent

246 with low risk of weak-instrument bias) (**Supplemental Tables 3-4**). The primary analysis  
247 maintained power to detect a 7% - 11% increase in risk of ASCVD per 10mmHg increase in  
248 blood pressure (**Supplemental Table 4**). In inverse-variance weighted analyses, each 10mmHg  
249 increase in SBP increased risk of both PAD (OR 1.25; 95% CI 1.19-1.31;  $p = 3 \times 10^{-18}$ ) and CAD  
250 (OR 1.37; 95% CI 1.29-1.45;  $p = 2 \times 10^{-24}$ ), though the effect was stronger for CAD than PAD  
251 ( $p_{\text{difference}} = 0.024$ ) (**Figure 1, Supplemental Table 5**). Each 10mmHg increase in DBP increased  
252 risk of both PAD (OR 1.27; 95% CI 1.17-1.39;  $p = 4 \times 10^{-8}$ ) and CAD (OR 1.6; 95% CI 1.45-1.76;  $p =$   
253  $7 \times 10^{-22}$ ), with a stronger effect for CAD than PAD ( $p_{\text{difference}} = 4.9 \times 10^{-4}$ ) (**Figure 1,**  
254 **Supplemental Table 5**). Each 10mmHg increase in PP increased risk of both PAD (OR 1.51; 95%  
255 CI 1.38-1.64;  $p = 1 \times 10^{-20}$ ) and CAD (OR 1.56; 95% CI 1.4-1.75;  $p = 1 \times 10^{-15}$ ), with similar effects  
256 on CAD and PAD ( $p_{\text{difference}} = 0.60$ ) (**Figure 1, Supplemental Table 5**). MR-Egger bias intercept  
257 term was  $p > 0.05$  for all trait-outcome pairs except PP-PAD ( $p = 0.012$ ) (**Supplemental Table 5**).  
258 Results remained robust in sensitivity analyses using MR methods that make different  
259 assumptions about the presence of pleiotropy (**Supplemental Table 5**).

260

## 261 **Effects of Liability to ASCVD on Blood Pressure: Mendelian Randomization**

262 Because stiffening of peripheral vessels in the setting of peripheral artery disease may  
263 affect blood pressure, raising the possibility of reverse-causation in assessment of the  
264 relationship between blood pressure and PAD, bi-directional MR analysis was performed.  
265 Genetic instruments for PAD and CAD were selected and used to estimate the effect of liability  
266 to ASCVD on blood pressure traits (**Figure 2; Supplemental Tables 6-7**). In inverse-variance  
267 weighted analysis, liability to PAD increased PP (beta = 0.97 mmHg per 1 log-odds increase in

268 risk of PAD; 95% CI 0.4-1.5;  $p = 8 \times 10^{-4}$ ), and CAD increased PP (beta = 0.542 per 1 log-odds  
269 increase in risk of CAD; 95% CI 0.006-1.1;  $p = 0.05$ . Neither PAD nor CAD affected SBP or DBP.  
270 The MR-Egger bias intercept term had  $p > 0.05$  for all analyses, indicating no positive evidence  
271 for bias. In sensitivity analysis applying MR methods making different assumptions about the  
272 presence of pleiotropy, there was weak evidence that both PAD and CAD increase SBP and PP  
273 while decreasing DBP (**Supplemental Table 7**).

274

### 275 **Multivariable Mendelian Randomization**

276 Because blood pressure traits are highly correlated and unlikely to affect cardiovascular  
277 outcomes in isolation, we performed multivariable MR to jointly estimate the direct effects of  
278 each blood pressure trait on ASCVD outcomes (**Supplemental Table 8**). Each 10mmHg increase  
279 in SBP increased risk of both PAD (direct OR 1.67; 95% CI 1.19-2.34;  $p = 0.003$ ) and CAD (direct  
280 OR 1.44; 95% CI 1.02-2.03;  $p = 0.04$ ). After accounting for the effect of SBP, we did not observe  
281 residual evidence of a significant direct effect of DBP on PAD or CAD.

282

### 283 **Antihypertensive Drug Mendelian Randomization**

284 Two Mendelian randomization analyses were performed to estimate the effect of blood  
285 pressure lowering on ASCVD outcomes. The first analysis focused on the effect of SBP lowering  
286 using genetic variants located within genes encoding protein targets of common classes of  
287 blood pressure lowering medications (ACE-inhibitors, beta-blockers, and calcium channel  
288 blockers) (**Figure 3; Supplemental Tables 10-11**). This analysis identified protective effects of  
289 beta-blocker-associated variants on CAD (OR 0.59 per 10mmHg decrease in SBP; 95% CI 0.44-

290 0.78;  $p = 3 \times 10^{-4}$ ), and protective effects of calcium channel blocker associated variants on CAD  
291 (OR 0.69 per 10mmHg decrease in SBP; 95% CI 0.59-0.80;  $p = 2 \times 10^{-6}$ ). No effect of blood  
292 pressure lowering via genetic proxies of these medication classes on risk of PAD was detected.  
293 Results were consistent in weighted-median MR sensitivity analyses (**Supplemental Table 11**).

294 In the second analysis, the effects of both SBP and DBP lowering conferred by genetic  
295 variants located within targets of a broader set of antihypertensive medications were  
296 considered (**Supplemental Tables 12-13**). Results for SBP were similar to the first analysis,  
297 identifying protective effects of calcium channel blocker associated variants on CAD (OR 0.64  
298 per 10mmHg decrease in SBP; 95% CI 0.50-0.81;  $p = 2 \times 10^{-4}$ ), vasodilator associated variants on  
299 CAD (OR 0.62 per 10mmHg decrease in SBP; 95% CI 0.40-0.95;  $p = 0.03$ ), and angiotensin II  
300 receptor antagonist associated variants on CAD (OR 0.30 per 10mmHg decrease in SBP; 95% CI  
301 0.097-0.95;  $p = 0.04$ ). Though not associated with CAD, SBP lowering via beta-blocker  
302 associated variants decreased risk of PAD (OR 0.51 10mmHg decrease in SBP; 95% CI 0.27-0.97;  
303  $p = 0.04$ ). Only results for calcium channel blocker associated variants were robust in weighted-  
304 median sensitivity analyses.

305 For diastolic blood pressure, lowering via calcium channel blocker associated variants  
306 decreased risk of CAD (OR 0.52 per 10mmHg decrease in DBP; 95% CI 0.34-0.78;  $p = 0.002$ ),  
307 lowering via angiotensin II receptor antagonist associated variants decreased risk of CAD (OR  
308 0.11 per 10mmHg decrease in DBP; 95% CI 0.014-0.91;  $p = 0.04$ ), lowering via beta-blocker  
309 associated variants decreased risk of CAD (OR 0.43 per 10mmHg decrease in DBP; 95% CI 0.19-  
310 1;  $p = 0.05$ ), and lowering via thiazide diuretic associated variants increased risk of PAD (OR 2.97  
311 per 10mmHg decrease in DBP; 95% CI 1.1-8;  $p = 0.03$ ). Only results for calcium channel blocker

312 associated variants were robust in weighted-median sensitivity analyses (**Supplemental Table**  
313 **13**).

314

## 315 **DISCUSSION**

316 This Mendelian randomization study leveraged natural genetic variation in blood  
317 pressure in up to 757,601 individuals to examine the relationship between blood pressure and  
318 both PAD and CAD. The principal findings were: 1) Lifetime exposure to elevated SBP, DBP, and  
319 PP all increased risk of PAD and CAD; 2) Elevated SBP and DBP more strongly increased risk of  
320 CAD compared to PAD; 3) PAD led to a small but significant increase in PP; 4) Based on genetic  
321 proxies, the optimal antihypertensive regimens for prevention/treatment of PAD remains  
322 unclear. There are several implications from the results of this study.

323 First, this study supports observational findings that elevated blood pressure is  
324 associated with increased risk of PAD. Multiple observational studies have identified elevated  
325 SBP and clinical diagnosis of hypertension as strong risk factors for PAD, while the relationship  
326 between DBP and PAD has remained less clear (5–11,25–27). Unlike other observational  
327 studies, our MR study leveraged genetic variants as instrumental variables for SBP, DBP, and PP.  
328 Because genetic variants are randomly inherited by offspring from their parents, mimicking a  
329 trial randomizing individuals to a lifetime of increased blood pressure, the Mendelian  
330 randomization framework is less susceptible to residual environmental confounding than  
331 traditional observational studies (14). The finding of our MR analysis that elevated SBP  
332 increases risk of both PAD and CAD is consistent with prior studies. We also find a strong effect  
333 of DBP on both PAD and CAD, clarifying discrepant findings in prior observational studies.

334 Overall, the MR findings of our study are consistent with a causal relationship between blood  
335 pressure traits and both PAD and CAD.

336 Next, we found that elevated SBP and DBP each increased risk of CAD more than PAD.  
337 These findings are in contrast to a prior observational analysis that found that SBP or DBP had  
338 similar effects on CAD and PAD (7). While broad recommendations for lifestyle modification  
339 and treatment of ASCVD risk factors are clearly important at both the population level and  
340 individual level, understanding the impact of interventions on specific ASCVD outcomes may  
341 further inform treatment and prevention guidelines and discussions with patients. Particularly  
342 in light of our recent finding that smoking more strongly increases risk of PAD in comparison to  
343 CAD or ischemic stroke (28), this study adds further nuance to the relationship between  
344 traditional ASCVD risk factors and specific ASCVD outcomes.

345 Our finding that increased pulse pressure increases PAD risk is consistent with findings  
346 from multiple prior observational studies (29–32). Because increased pulse pressure is a marker  
347 of increased arterial stiffness and may be caused by PAD, the observational studies  
348 investigating the relationship between these traits may have been limited by the possibility of  
349 reverse causality. Using bi-directional MR we were able to overcome this limitation, finding  
350 elevated PP to be a risk factor for PAD, and PAD to be a risk factor for increased PP. Our  
351 multivariable MR analysis of SBP and DBP suggests the effect of elevated DBP may be  
352 attenuated after accounting for the genetic effect of SBP. In other words, holding diastolic  
353 blood pressure constant, the effect of blood pressure on ASCVD is due to the effects of  
354 increased SBP (and indirectly, increased PP). These findings lend further support for the role of  
355 increased PP on PAD.

356 Finally, we used antihypertensive drug MR to estimate the effect of 10mmHg lowering  
357 of blood pressure by different classes of medication. In this analysis, we identified a protective  
358 effect of calcium-channel blockers on risk of CAD, consistent across all sensitivity analyses.  
359 Confidence intervals for other drug classes were wide, and did not exclude meaningful effects,  
360 which may reflect the small number of genetic variants included in the genetic instruments for  
361 each antihypertensive drug class. More robust genetic instruments may ultimately reveal  
362 additional antihypertensive drug classes that robustly lower ASCVD risk. Similarly, because  
363 increased SBP and DBP more strongly affected risk of CAD than PAD, the lack of effect of  
364 medication-specific SBP or DBP-lowering instruments and PAD is not surprising. While small  
365 beneficial genetic effects may compound over a lifetime leading to protection from ASCVD, the  
366 effects of antihypertensive medications occur on a much shorter timescale. Our findings do not  
367 exclude beneficial effects of potent antihypertensive medications on risk of PAD and CAD,  
368 particularly given the strong causal effects of each BP trait and each ASCVD outcome.

369 The overall findings of our study have implications for PAD prevention and treatment  
370 guidelines. The current 2016 American Heart Association/American College of Cardiology  
371 (AHA/ACC) and 2017 European Society of Cardiology (ESC) PAD guidelines make strong  
372 recommendations for the treatment of hypertension to prevent cardiovascular events.(3,4) The  
373 trials cited to support these recommendations focused on cardiovascular events broadly, or  
374 differences in safety and efficacy between different antihypertensive classes, rather than PAD-  
375 specific outcomes (33–41). A Cochrane Review found poor evidence for the use of  
376 antihypertensive medications specifically for PAD, though recognized the large benefit of these  
377 medications for prevention of cardiovascular events and mortality more broadly (42). Our MR

378 study provides strong evidence consistent with a casual effect of increased blood pressure on  
379 PAD. In the absence of large randomized trials of antihypertensive medications focused on  
380 PAD-specific outcomes, these results add support for current guideline recommendations.  
381 Further, these results may help calibrate the expected benefit that programs to treat  
382 hypertension may have on the global burden of PAD.

383         This study has several potential limitations. The genetic studies of blood pressure, CAD,  
384 and PAD used in our analysis were primarily composed of individuals of European ancestry.  
385 Further study of BP and ASCVD genetics in diverse ancestral populations is necessary to  
386 improve the generalizability of our findings. Mendelian randomization relies on a number of  
387 assumptions in order for causal estimates to be valid (14). While we have employed multiple  
388 MR methods and sensitivity analyses to assess for and address potential violations of these  
389 assumptions, we cannot completely exclude the possibility of confounding. Future study on the  
390 role of hypertension treatment in the prevention and treatment of PAD focused on PAD-specific  
391 outcomes is warranted.

392         Overall, we find strong evidence consistent with a causal effect of blood pressure traits  
393 on ASCVD outcomes, with a stronger effect of SBP and DBP on CAD in comparison to PAD.  
394 Further study of the differential effects of traditional ASCVD risk factors on specific ASCVD  
395 outcomes may help guide prevention and treatment strategies for these common diseases.

396

397 **FUNDING:**

398 This work was supported by US Department of Veterans Affairs grants IK2-CX001780  
399 (Damrauer), and I01-BX003362 (Tsao/Chang). This research is based on data from the MVP,

400 Office of Research and Development, Veterans Health Administration and was supported by  
401 award no. MVP000. This publication does not represent the views of the Department of  
402 Veterans Affairs or the United States government. This work was also supported by the  
403 National Institute of Diabetes and Digestive and Kidney Diseases R01-DK101478 (Voight), and a  
404 Linda Pechenik Montague Investigator Award (Voight). The Medical Research Council (MRC)  
405 and the University of Bristol support the MRC Integrative Epidemiology Unit [MC\_UU\_12013/1,  
406 MC\_UU\_12013/9, MC\_UU\_00011/1]. NMD is supported by a Norwegian Research Council  
407 Grant number 295989.

408

409 **DATA AVAILABILITY:**

410 Summary statistics for the blood pressure genome wide association study are publicly available,  
411 and may be downloaded from the NHLBI GRASP catalog  
412 (<https://grasp.nhlbi.nih.gov/FullResults.aspx>). MVP PAD genome wide association study  
413 summary statistics are available on dbGAP (Accession phs001672.v2.p1). Data on coronary  
414 artery disease have been contributed by CARDIoGRAMplusC4D investigators and have been  
415 downloaded from [www.cardiogramplusc4d.org/data-downloads/](http://www.cardiogramplusc4d.org/data-downloads/).

416

417 **REFERENCES:**

- 418 1. James SL, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, et al. Global, regional, and  
419 national incidence, prevalence, and years lived with disability for 354 Diseases and  
420 Injuries for 195 countries and territories, 1990-2017: A systematic analysis for the Global  
421 Burden of Disease Study 2017. *Lancet*. 2018 Nov 10;1789–858.

- 422 2. Criqui MH, Aboyans V. Epidemiology of Peripheral Artery Disease. *Circ Res*. 2015 Apr  
423 24;116(9):1509–26.
- 424 3. Gerhard-Herman MD, Gornik HL, Barrett C, Barshes NR, Corriere MA, Drachman DE, et al.  
425 2016 Lower Extremity Peripheral Arterial Disease Guidelines. *J Am Coll Cardiol*.  
426 2017;69(11):e71–126.
- 427 4. Aboyans V, Ricco J-B, Bartelink M-LEL, Björck M, Brodmann M, Cohnert T, et al. 2017 ESC  
428 Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in  
429 collaboration with the European Society for Vascular Surgery (ESVS): Document covering  
430 atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal,. *Eur*  
431 *Heart J* [Internet]. 2017 Aug 26;39(9):763–816. Available from:  
432 <https://doi.org/10.1093/eurheartj/ehx095>
- 433 5. Bainton D, Sweetnam P, Baker I, Elwood P. Peripheral vascular disease: consequence for  
434 survival and association with risk factors in the Speedwell prospective heart disease  
435 study. *Heart* [Internet]. 1994 Aug 1 [cited 2019 Oct 10];72(2):128–32. Available from:  
436 <http://heart.bmj.com/cgi/doi/10.1136/hrt.72.2.128>
- 437 6. Criqui MH, Vargas V, Denenberg JO, Ho E, Allison M, Langer RD, et al. Ethnicity and  
438 peripheral arterial disease: The San Diego population study. *Circulation*. 2005 Oct  
439 25;112(17):2703–7.
- 440 7. Gerald F, Housley E, Riemersma RA, Macintyre CCA, Cawood EHH, Prescott RJ, et al.  
441 Smoking, lipids, glucose intolerance, and blood pressure as risk factors for peripheral  
442 atherosclerosis compared with ischemic heart disease in the Edinburgh artery study. *Am*  
443 *J Epidemiol*. 1992 Feb 15;135(4):331–40.

- 444 8. Hooi JD, Kester ADM, Stoffers HEJH, Overdijk MM, Van Ree JW, Knottnerus JA. Incidence  
445 of and risk factors for asymptomatic peripheral arterial occlusive disease: A longitudinal  
446 study. *Am J Epidemiol*. 2001 Apr 1;153(7):666–72.
- 447 9. Dagenais GR, Maurice S, Robitaille NM, Gingras S, Lupien PJ. Intermittent claudication in  
448 Quebec men from 1974-1986: the Quebec Cardiovascular Study. *Clin Invest Med*  
449 [Internet]. 1991 Apr [cited 2019 Oct 10];14(2):93–100. Available from:  
450 <http://www.ncbi.nlm.nih.gov/pubmed/2060193>
- 451 10. Garg PK, Biggs ML, Carnethon M, Ix JH, Criqui MH, Britton KA, et al. Metabolic syndrome  
452 and risk of incident peripheral artery disease: The cardiovascular health study.  
453 *Hypertension*. 2014 Feb;63(2):413–9.
- 454 11. D.P.J. H, A. B, J.F. F, L. H, L.E. S, P.M. R, et al. Population-Based Study of Incidence, Risk  
455 Factors, Outcome, and Prognosis of Ischemic Peripheral Arterial Events: Implications for  
456 Prevention. *Circulation* [Internet]. 2015 [cited 2019 Oct 10];132(19):1805–15. Available  
457 from:  
458 [http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L6064](http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L606470115)  
459 [70115](http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L606470115)
- 460 12. Klarin D, Lynch J, Aragam K, Chaffin M, Assimes TL, Huang J, et al. Genome-wide  
461 association study of peripheral artery disease in the Million Veteran Program. *Nat Med*  
462 [Internet]. 2019 Jul 8 [cited 2019 Jul 28]; Available from:  
463 <http://www.nature.com/articles/s41591-019-0492-5>
- 464 13. Nikpay M, Goel A, Won HH, Hall LM, Willenborg C, Kanoni S, et al. A comprehensive 1000  
465 Genomes-based genome-wide association meta-analysis of coronary artery disease. *Nat*

- 466 Genet. 2015;47(10):1121–30.
- 467 14. Davies NM, Holmes M V, Davey Smith G. Reading Mendelian randomisation studies: A  
468 guide, glossary, and checklist for clinicians. *BMJ* [Internet]. 2018 Jul 12 [cited 2019 Feb  
469 15];362:k601. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/30002074>
- 470 15. Evangelou E, Warren HR, Mosen-Ansorena D, Mifsud B, Pazoki R, Gao H, et al. Genetic  
471 analysis of over 1 million people identifies 535 new loci associated with blood pressure  
472 traits. *Nat Genet*. 2018 Oct 1;50(10):1412–25.
- 473 16. Bulik-Sullivan BK, Loh P-R, Finucane HK, Ripke S, Yang J, Patterson N, et al. LD Score  
474 regression distinguishes confounding from polygenicity in genome-wide association  
475 studies. *Nat Genet* [Internet]. 2015 Mar 2 [cited 2019 Feb 13];47(3):291–5. Available  
476 from: <http://www.nature.com/articles/ng.3211>
- 477 17. Bulik-Sullivan B, Finucane HK, Anttila V, Gusev A, Day FR, Loh PR, et al. An atlas of genetic  
478 correlations across human diseases and traits. *Nat Genet*. 2015 Nov 1;47(11):1236–41.
- 479 18. Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, et al. The MR-base  
480 platform supports systematic causal inference across the human phenome. *Elife*. 2018;
- 481 19. Shim H, Chasman DI, Smith JD, Mora S, Ridker PM, Nickerson DA, et al. A multivariate  
482 genome-wide association analysis of 10 LDL subfractions, and their response to statin  
483 treatment, in 1868 Caucasians. *PLoS One*. 2015;
- 484 20. Palmer TM, Lawlor DA, Harbord RM, Sheehan NA, Tobias JH, Timpson NJ, et al. Using  
485 multiple genetic variants as instrumental variables for modifiable risk factors. *Stat*  
486 *Methods Med Res* [Internet]. 2012 Jun 7 [cited 2019 Mar 24];21(3):223–42. Available  
487 from: <http://journals.sagepub.com/doi/10.1177/0962280210394459>


- 488 21. Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent Estimation in Mendelian  
489 Randomization with Some Invalid Instruments Using a Weighted Median Estimator.  
490 Genet Epidemiol [Internet]. 2016 May [cited 2019 Feb 28];40(4):304–14. Available from:  
491 <http://www.ncbi.nlm.nih.gov/pubmed/27061298>
- 492 22. Sanderson E, Davey Smith G, Windmeijer F, Bowden J. An examination of multivariable  
493 Mendelian randomization in the single-sample and two-sample summary data settings.  
494 Int J Epidemiol. 2019 Jun 1;48(3):713–27.
- 495 23. Gill D, Georgakis MK, Koskeridis F, Jiang L, Feng Q, Wei W-Q, et al. Use of Genetic  
496 Variants Related to Antihypertensive Drugs to Inform on Efficacy and Side Effects.  
497 Circulation. 2019 Jul 23;140(4):270–9.
- 498 24. Walker VM, Kehoe PG, Martin RM, Davies NM. Repurposing antihypertensive drugs for  
499 the prevention of Alzheimer’s disease: a Mendelian randomization study. Int J Epidemiol.  
500 2019 Jul 23;
- 501 25. Meijer WT, Grobbee DE, Hunink MGM, Hofman A, Hoes AW. Determinants of peripheral  
502 arterial disease in the elderly: The Rotterdam Study. Arch Intern Med. 2000 Oct  
503 23;160(19):2934–8.
- 504 26. Newman AB, Siscovick DS, Manolio TA, Polak J, Fried LP, Borhani NO, et al. Ankle-arm  
505 index as a marker of atherosclerosis in the cardiovascular health study. Circulation.  
506 1993;88(3):837–45.
- 507 27. McGee DL. Update on Some Epidemiologic Features of Intermittent Claudication: The  
508 Framingham Study. J Am Geriatr Soc. 1985;33(1):13–8.
- 509 28. Levin MG, Klarin D, Assimes TL, Freiberg MS, Ingelsson E, Lynch J, et al. Genetics of

- 510 Smoking and Risk of Atherosclerotic Cardiovascular Diseases: A Mendelian  
511 Randomization Study. medRxiv. 2020 Apr 8;2020.04.07.20053447.
- 512 29. Mao Y, Huang Y, Yu H, Xu P, Yu G, Yu J, et al. Incidence of peripheral arterial disease and  
513 its association with pulse pressure: A prospective cohort study. *Front Endocrinol*  
514 (Lausanne). 2017 Nov 24;8(NOV).
- 515 30. Zhan Y, Yu J, Chen R, Sun Y, Fu Y, Zhang L, et al. Prevalence of low ankle brachial index  
516 and its association with pulse pressure in an elderly Chinese population: a cross-sectional  
517 study. *J Epidemiol [Internet]*. 2012 [cited 2019 Oct 10];22(5):454–61. Available from:  
518 <http://www.ncbi.nlm.nih.gov/pubmed/22813646>
- 519 31. Korhonen P, Kautiainen H, Aarnio P. Pulse pressure and subclinical peripheral artery  
520 disease. *J Hum Hypertens [Internet]*. 2014 Apr [cited 2019 Oct 10];28(4):242–5. Available  
521 from: <http://www.ncbi.nlm.nih.gov/pubmed/24132137>
- 522 32. Kiuchi S, Hisatake S, Watanabe I, Toda M, Kabuki T, Oka T, et al. Pulse Pressure and  
523 Upstroke Time Are Useful Parameters for the Diagnosis of Peripheral Artery Disease in  
524 Patients With Normal Ankle Brachial Index. *Cardiol Res [Internet]*. 2016 Oct [cited 2019  
525 Oct 10];7(5):161–6. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/28197286>
- 526 33. Ostergren J, Sleight P, Dagenais G, Danisa K, Bosch J, Qilong Y, et al. Impact of ramipril in  
527 patients with evidence of clinical or subclinical peripheral arterial disease. *Eur Heart J*  
528 [Internet]. 2004 Jan [cited 2019 Oct 10];25(1):17–24. Available from:  
529 <http://www.ncbi.nlm.nih.gov/pubmed/14683738>
- 530 34. Yusuf S. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on  
531 cardiovascular events in high-risk patients. *N Engl J Med*. 2000 Jan 20;342(3):145–53.

- 532 35. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, et al. Telmisartan, ramipril, or  
533 both in patients at high risk for vascular events. *N Engl J Med*. 2008 Apr 10;358(15):1547–  
534 59.
- 535 36. Bavry AA, Anderson RD, Gong Y, Denardo SJ, Cooper-Dehoff RM, Handberg EM, et al.  
536 Outcomes Among hypertensive patients with concomitant peripheral and coronary  
537 artery disease: findings from the INternational VErapamil-SR/Trandolapril STudy.  
538 *Hypertens (Dallas, Tex 1979) [Internet]*. 2010 Jan [cited 2019 Oct 10];55(1):48–53.  
539 Available from: <http://www.ncbi.nlm.nih.gov/pubmed/19996066>
- 540 37. Zanchetti A, Julius S, Kjeldsen S, McInnes GT, Hua T, Weber M, et al. Outcomes in  
541 subgroups of hypertensive patients treated with regimens based on valsartan and  
542 amlodipine: An analysis of findings from the VALUE trial. *J Hypertens [Internet]*. 2006  
543 Nov [cited 2019 Oct 10];24(11):2163–8. Available from:  
544 <http://www.ncbi.nlm.nih.gov/pubmed/17053536>
- 545 38. Diehm C, Pittrow D, Lawall H. Effect of nebivolol vs. hydrochlorothiazide on the walking  
546 capacity in hypertensive patients with intermittent claudication. *J Hypertens [Internet]*.  
547 2011 Jul [cited 2019 Oct 10];29(7):1448–56. Available from:  
548 <http://www.ncbi.nlm.nih.gov/pubmed/21602713>
- 549 39. Espinola-Klein C, Weisser G, Jagodzinski A, Savvidis S, Warnholtz A, Ostad M-A, et al.  $\beta$ -  
550 Blockers in patients with intermittent claudication and arterial hypertension: results from  
551 the nebivolol or metoprolol in arterial occlusive disease trial. *Hypertens (Dallas, Tex*  
552 *1979) [Internet]*. 2011 Aug [cited 2019 Oct 10];58(2):148–54. Available from:  
553 <http://www.ncbi.nlm.nih.gov/pubmed/21646599>

- 554 40. Paravastu SCV, Mendonca DA, Da Silva A. Beta blockers for peripheral arterial disease.  
555 Cochrane database Syst Rev [Internet]. 2013 Sep 11 [cited 2019 Oct 10];(9):CD005508.  
556 Available from: <http://www.ncbi.nlm.nih.gov/pubmed/24027118>
- 557 41. Group TAO and C for the ACR, Coordinators TAO and, Antihypertensive T, Treatment L.  
558 Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-  
559 Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic. JAMA J Am Med  
560 Assoc [Internet]. 2002 [cited 2019 Oct 10];288(23):2981–97. Available from:  
561 <http://www.ncbi.nlm.nih.gov/pubmed/12479763>
- 562 42. Lane DA, Lip GYH. Treatment of hypertension in peripheral arterial disease. Vol. 2013,  
563 Cochrane Database of Systematic Reviews. John Wiley and Sons Ltd; 2013.  
564

565 **Figure 1:** Effect of Blood Pressure Traits on ASCVD Outcomes




566

567 In inverse variance weighted Mendelian randomization analyses, elevations in each blood pressure trait increased risk of both  
 568 coronary and peripheral artery disease. Results scaled to reflect odds of outcome per 10mmHg increase in blood pressure. n SNP =  
 569 number of single nucleotide polymorphisms in the exposure instrument; OR = odds ratio; 95% CI = 95% confidence interval; P = p-  
 570 value SBP = Systolic blood pressure; DBP = Diastolic blood pressure; PP = Pulse pressure; PAD = Peripheral artery disease; CAD =  
 571 coronary artery disease.

572

573 **Figure 2:** Effect of ASCVD Traits on Blood Pressure



574

575 In inverse variance weighted Mendelian randomization analyses, both peripheral artery disease and coronary artery disease

576 increased pulse pressure. Results reflect increase in blood pressure (mmHg per 1 log-odds unit increase in risk of the exposure). n

577 SNP = number of single nucleotide polymorphisms in the exposure instrument; OR = odds ratio; 95% CI = 95% confidence interval; P


578 = p-value SBP = Systolic blood pressure; DBP = Diastolic blood pressure; PP = Pulse pressure; PAD = Peripheral artery disease; CAD =

579 coronary artery disease.

580

581 **Figure 3:** Mendelian Randomization Estimates of the Effect of Systolic Blood Pressure Lowering Through Antihypertensive

582 Medication-associated Genetic Variants



583


584 Results scaled to reflect odds of outcome per 10mmHg decrease in blood pressure. n SNP = number of single nucleotide

585 polymorphisms in the exposure instrument; OR = odds ratio; 95% CI = 95% confidence interval; P = p-value SBP = Systolic blood

586 pressure; DBP = Diastolic blood pressure; PP = Pulse pressure; PAD = Peripheral artery disease; CAD = coronary artery disease.

587


588 **Supplemental Figure 1:** Genetic Correlation Between Blood Pressure Traits



589

590

591 **Supplemental Figure 2:** Genetic Correlation Between Blood Pressure and ASCVD Traits



592

593